Humanetics’ Treatment for Erectile Dysfunction in Radiation-treated Patients, BIO 300, Given Patent

Humanetics’ Treatment for Erectile Dysfunction in Radiation-treated Patients, BIO 300, Given Patent
Humanetics Corporation has received a U.S. patent for its BIO 300 compound, which it developed to prevent erectile dysfunction in men receiving radiation therapy for prostate cancer. Two professors at the University of Maryland School of Medicine, Dr. Zeljko Vujaskovic, MD, and Dr. Isabel L. Jackson, PhD, developed BIO 300. Preclinical studies a few years ago showed that the compound not only can mitigate radiation-induced erectile dysfunction, but can also improve radiotherapy's ability to kill tumors. The research, "Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer," was published in 2010 in Nutrition and Cancer. After skin cancer, prostate cancer is the most common cancer in American men, with the American Cancer Society predicting 161,360 new cases in 2017. The most common way to treat patients with localized prostate cancer is external beam radiation. But the procedure can have side effects, such as incontinence or erectile dysfunction, that impact a patient's quality of life. Researchers have found that BIO 300 can be both a radioprotector, preventing or reducing radiation damage to normal tissue, and a radiosensitizer, increasing radiation's ability to kill tumors. The compound is a nanoparticle containing a substance called genistein that occurs naturally in plants. In a pilot study with 42 patients, researchers assessed BIO 300's
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *